RAD001 and Octreotide LAR as first-line treatment of well differentiated neuroendocrine tumors: an I.T.M.O. (Italian Trials in Medical Oncology) group study
Introduction: RAD001 has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with somatostatine analogues.
Aim(s): The primary objective of this multicentric study is to assess the activity and safety of RAD001 and Octreotide LAR as first-line treatment of lung and gastro-entero-pancreatic (GEP) NETs.
Materials and methods: From March 2009 to June 2010, 50 patients (pts) (21 female and 29 male) were treated with RAD001 10 mg/day and Octreotide LAR 30 mg/month, until disease progression and/or unacceptable toxicity. Forty-two pts had a GEP NET and 8 had a lung carcinoid. The median age was 60.5 yrs (range 25-76).
To read the full abstract, please log into your ENETS Member account.